GlassScriptPhysician profile
Carlos E Fonte
NPI 1215979604
$7,782.11
in general payments reported to CMS, 2019-2025
33 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $1,059 · 2021: $1,614 · 2022: $1,828 · 2023: $863 · 2024: $554 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878 · Education: $5.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.63 |
| Education | $5.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,599.16 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,189.67 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $880.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $543.33 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $410.36 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.51 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $367.01 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $271.54 | 2021-2023 | Verquvo |
| Nevro Corp. | $239.63 | 2019 | |
| Amarin Pharma, INC. | $224.07 | 2019-2022 | |
| Medtronic Vascular, INC. | $207.90 | 2020 | |
| Impulse Dynamics (USA) INC. | $174.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.24 | 2021-2023 | |
| Esperion Therapeutics, INC. | $139.31 | 2020-2021 | |
| Abbott Laboratories | $112.17 | 2019-2025 | Jot Dx |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $107.17 | 2019-2024 | |
| Astellas Pharma US INC | $98.67 | 2019-2021 | |
| Novo Nordisk INC | $96.04 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Alnylam Pharmaceuticals INC. | $88.97 | 2021-2025 | Amvuttra |
| Boston Scientific Corporation | $83.07 | 2020-2023 | Varithena Administration Pack |
| Bard Peripheral Vascular, INC. | $71.62 | 2021-2025 | Venclose Maven Catheter |
| Kowa Pharmaceuticals America, INC. | $60.71 | 2020-2021 | |
| Irhythm Technologies, INC. | $45.85 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $41.57 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $32.50 | 2023 | |
| Edwards Lifesciences Corporation | $31.86 | 2021 | |
| Lundbeck LLC | $24.68 | 2019 | |
| Bardy Diagnostics, INC. | $19.00 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $15.37 | 2019 | |
| Koya Medical, INC. | $15.20 | 2025 | Dayspring, Koya Medical |
| Medtronic, INC. | $15.11 | 2021 | |
| Tactile Systems Technology INC | $14.64 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Fonte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.